3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
31
Carcinoma, Renal Cell
19
Carcinoma, Non-Small-Cell Lung
19
Neoplasm Metastasis
11
Carcinoma, Hepatocellular
9
Brain Neoplasms
8
Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Clear-cell metastatic renal cell carcinoma
5
Carcinoma, Transitional Cell
5
Uveal Melanoma
4
Skin Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Multiple Myeloma
4
Mesothelioma
4
Kidney Neoplasms
4
Glioblastoma
4
Carcinoma, Basal Cell
4
Carcinoma
4
Sarcoma
3
Recurrence
3
Myelodysplastic Syndromes
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Gliosarcoma
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
talazoparib
1
olaparib
1
irinotecan sucrosofate
1
amino-acid, glucose, and electrolyte solution
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Liquid Biopsy
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Ipilimumab
×
90 days
×
Clear all
No trials found.